AAA
Affinity Asset Advisors Portfolio holdings
AUM
$676M
This Quarter Return
-5.47%
1 Year Return
+29.75%
3 Year Return
+452.89%
5 Year Return
–
10 Year Return
–
AUM
$183M
AUM Growth
+$183M
(-28%)
Cap. Flow
-$39.6M
Cap. Flow
% of AUM
-21.71%
Top 10 Holdings %
Top 10 Hldgs %
66.27%
Holding
69
New
6
Increased
13
Reduced
11
Closed
14
Top Buys
| 1 |
Establishment Labs
ESTA
|
$10.1M |
| 2 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
$4.74M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$3.59M |
| 4 |
Madrigal Pharmaceuticals
MDGL
|
$1.79M |
| 5 |
Lantheus
LNTH
|
$1.65M |
Top Sells
| 1 |
SWTX
SpringWorks Therapeutics
SWTX
|
$13.9M |
| 2 |
Protagonist Therapeutics
PTGX
|
$7.1M |
| 3 |
NSTG
NanoString Technologies, Inc.
NSTG
|
$5.96M |
| 4 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
$5.42M |
| 5 |
AstraZeneca
AZN
|
$4.96M |
Sector Composition
| 1 | Healthcare | 82.95% |
| 2 | Financials | 1.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Establishment Labs
ESTA
$1.2B
| $19.6M | 8.25% | 359,956 +185,456 | +106% | +$10.1M |
|
2
Kura Oncology
KURA
$686M
| $17M | 7.17% | 928,256 +4,109 | +0.4% | +$75.3K |
|
|
KDNY
3
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $16.4M | 6.91% | 937,568 +92,413 | +11% | +$1.62M |
|
|
NARI
4
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $15.1M | 6.37% | 222,173 +2,173 | +1% | +$148K |
|
5
Ascendis Pharma
ASND
$11.8B
| $11.6M | 4.9% | 125,087 +5,087 | +4% | +$473K |
|
|
6
Lantheus
LNTH
$3.73B
| $9.24M | 3.9% | 140,000 +25,000 | +22% | +$1.65M |
|
|
7
Madrigal Pharmaceuticals
MDGL
$9.76B
| $7.16M | 3.02% | 100,000 +25,000 | +33% | +$1.79M |
|
|
HZNP
8
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $5.98M | 2.52% | 75,000 +45,000 | +150% | +$3.59M |
|
|
KRTX
9
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $5.69M | 2.4% | 45,000 +37,500 | +500% | +$4.74M |
|
|
10
AstraZeneca
AZN
$248B
| $5.62M | 2.37% | 85,000 -75,000 | -47% | -$4.96M |
|
|
MORF
11
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $4.68M | 1.97% | 215,723 -249,931 | -54% | -$5.42M |
|
|
BLU
12
DELISTED
BELLUS Health Inc.
BLU
| $4.56M | 1.92% | 493,278 -106,722 | -18% | -$986K |
|
13
Repare Therapeutics
RPTX
$71.7M
| $4.49M | 1.89% | 321,200 -147,705 | -31% | -$2.07M |
|
|
CBAY
14
DELISTED
Cymabay Therapeutics
CBAY
| $4.05M | 1.71% | 1,372,244 +100,000 | +8% | +$295K |
|
15
Rocket Pharmaceuticals
RCKT
$354M
| $3.45M | 1.45% | 250,466 -49,534 | -17% | -$682K |
|
|
ARYE
16
DELISTED
ARYA Sciences Acquisition Corp V Class A Ordinary Shares
ARYE
| $3.43M | 1.44% | 352,500 -350,000 | -50% | -$3.4M |
|
17
Zentalis Pharmaceuticals
ZNTL
$122M
| $1.97M | 0.83% | 70,000 -137,500 | -66% | -$3.86M |
|
18
Context Therapeutics
CNTX
$75.4M
| $1.87M | 0.79% | 883,654 +106,044 | +14% | +$225K |
|
|
VINC
19
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
| $1.81M | 0.76% | 1,374,098 | – | – |
|
20
Aclaris Therapeutics
ACRS
$209M
| $1.4M | 0.59% | 100,000 | – | – |
|
21
Arcellx
ACLX
$3.85B
| $1.36M | 0.57% | +75,000 | New | +$1.36M |
|
22
Nautilus Biotechnolgy
NAUT
$85.9M
| $1.26M | 0.53% | 466,607 -92,412 | -17% | -$249K |
|
23
Cogent Biosciences
COGT
$1.69B
| $1.13M | 0.48% | +125,000 | New | +$1.13M |
|
24
Celldex Therapeutics
CLDX
$1.47B
| $1.08M | 0.45% | 40,000 -85,000 | -68% | -$2.29M |
|
25
Terns Pharmaceuticals
TERN
$609M
| $995K | 0.42% | +401,268 | New | +$995K |
|